This process activates these immune cells and induces the release of additional pro-inflammatory cytokines, i.e., IL1α, IL1β, TNFα, IFNγ, and IL17, which may exacerbate endothelial dysfunction and contribute to the degradation of the endothelial glycocalyx. The gene discussed is IL1B; the disease is endothelial dysfunction.